[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2007038453A2 - Administration d'un agent pour l'amelioration de l'inflammation - Google Patents

Administration d'un agent pour l'amelioration de l'inflammation Download PDF

Info

Publication number
WO2007038453A2
WO2007038453A2 PCT/US2006/037332 US2006037332W WO2007038453A2 WO 2007038453 A2 WO2007038453 A2 WO 2007038453A2 US 2006037332 W US2006037332 W US 2006037332W WO 2007038453 A2 WO2007038453 A2 WO 2007038453A2
Authority
WO
WIPO (PCT)
Prior art keywords
agent
vegf
ocular
inflammatory
formulation
Prior art date
Application number
PCT/US2006/037332
Other languages
English (en)
Other versions
WO2007038453A3 (fr
Inventor
Gholam Ali Peyman
Original Assignee
Advanced Ocular Systems Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/234,970 external-priority patent/US20070071754A1/en
Priority claimed from US11/348,465 external-priority patent/US20070072933A1/en
Priority claimed from US11/348,017 external-priority patent/US20070071756A1/en
Application filed by Advanced Ocular Systems Limited filed Critical Advanced Ocular Systems Limited
Publication of WO2007038453A2 publication Critical patent/WO2007038453A2/fr
Publication of WO2007038453A3 publication Critical patent/WO2007038453A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Definitions

  • This invention relates generally to methods for treating or preventing, in a patient, an inflammatory ailment using at least an anti-vascular endothelial growth factor (VEGF) agent. More particularly, the invention relates to an ocular prophylaxis or treatment method comprising ocularly providing to a patient having or at risk for developing an ocular inflammatory ailment a formulation comprising an anti-VEGF agent under conditions sufficient to ameliorate a cause and/or effect of fluid leakage in the eye.
  • VEGF anti-vascular endothelial growth factor
  • the invention also relates to an ocular prophylaxis or treatment method comprising the step of: ocularly providing to a patient, having or at risk for developing an ocular disease from fluid leakage from new ocular blood vessels to a surrounding area, a formulation comprising an anti-vascular endothelial growth factor (VEGF) agent selected from the group comprising bevacizumab, ranibizumab, pegaptanib, sunitinib maleate, TNP470, integrin av antagonists, 2-methoxyestradioi, paclitaxel, anti-VEGF siRNA, or P38 mitogen activated protein kinase inhibitors under conditions sufficient to ameliorate a cause and/or effect of fluid leakage in the eye.
  • VEGF anti-vascular endothelial growth factor
  • Inflammation is a localized, protective response of vascularized tissue to sub-lethal tissue injury or destruction.
  • the response functions to destroy, dilute, or sequester both the injurious agent and the injured tissue.
  • Inflammation can be classified according to duration as either acute or chronic.
  • classical signs are pain, heat, redness, swelling, and loss of function.
  • Histologically there are a complex series of events including dilatation of arterioles, capillaries and venules, with increased permeability and blood flow, exudation of fluids including plasma proteins, and leukocyte migration and accumulation at the site of injury.
  • This reaction may trigger a systemic response such as fever, leukocytosis, protein catabolism, and altered hepatic synthesis of plasma proteins such as C-reactive protein.
  • Chronic inflammation is characterized by macrophage and lymphocyte infiltration into the affected and surrounding tissue.
  • P[J$0Di3f& ⁇ laTftBa ⁇ !b3 is a homeostatic response to tissue damage by a range of stimuli, including infection and trauma.
  • an inflammatory response helps to destroy or inactivate invading pathogens.
  • inflammation is a response against self. The inflammatory process removes waste and debris and restores normal function, either through resolution or repair.
  • Tissue structure is normal after resolution, whereas repair leads to a functional, but morphologically altered, organ.
  • tissue damage is followed by resolution or healing by scar formation, whereas in chronic inflammation, damage and repair continue concurrently.
  • the initial inflammatory response is usually acute, and may or may not evolve into chronic inflammation.
  • chronic inflammation is not always preceded by an acute phase.
  • inflammation itself may lead to tissue damage, resulting in escalation of chronic inflammation.
  • Inflammation underlies the pathology of virtually all rheumatologic diseases. The severity of disorders, such as arthritis, is classified according to the degree of inflammation and its destructive effects.
  • Anti-VEGF agents affect the process of angiogenesis, which is the growth of new blood vessels from pre-existing vasculature. It is a fundamental process required for embryogenesis, growth, tissue repair after injury, and the female reproductive cycle. It also contributes to the pathology of conditions such as cancer, age related macular degeneration, psoriasis, diabetic retinopathy, and chronic inflammatory diseases in joints or lungs.
  • Angiogenesis is stimulated when hypoxic, diseased, or injured tissues produce and release angiogenic promoters such as VEGF, platelet derived growth factor (PDGF), or fibroblast growth factor (FGF)-I . These angiogenic factors stimulate the migration and proliferation of endothelial cells in existing vessels and, subsequently, the formation of capillary tubes and the recruitment of other cell types to generate and stabilize new blood vessels.
  • VEGF vascular endothelial growth factor
  • PDGF platelet derived growth factor
  • FGF fibroblast growth factor
  • Angiogenic factors may be pro-inflammatory factors. Relatively minor irritation of internal tissues, such as that which can occur during surgery, does not lead to neovascularization, but encourages tissue adhesion and scarring.
  • Agents that inhibit angiogenesis such as the previously disclosed TNP470, integrin av antagonists, 2-methoxyestradiol, paclitaxel, P38 mitogen activated protein kinase inhibitors, anti-VEGF siRNA, and sunitinib maleate (Sutent ® /SU11248) may inhibit !! i ; ritis, retinal vasculitis, optic nerve neuritis, papillitis, retinitis proliferation in diabetes, etc.
  • adhesion molecules such as integrin avb3 and e-selectin are upregulated in new vessels, and new vessels appear sensitive to inflammogens.
  • the angiogenic factor FGF-1 enhances antigen-induced synovitis in rabbits, but is not pro-inflammatory when administered alone.
  • angiogenesis occurs in the absence of inflammation, such as during embryonic growth and in the female reproductive cycle.
  • Angiogenesis enhances tumour growth, and anti-angiogenic agents are used clinically as a treatment modality.
  • Mechanisms by which new vessels enhance tumour growth include providing metabolic requirements of the tumour, generating growth factors by vascular cells, and inhibiting apoptosis. Inhibiting the function of growth factors such as VEGF can reduce or prevent pathological angiogenesis in tumours.
  • Angiogenesis may also contribute to thickening of airways in asthma and of lung parenchyma in pulmonary fibrosis, and to growth of sarcoid granulomas. Growth of granulation tissue into airspaces also may be angiogenesis-dependent in bronchi after lung transplant and in alveoli after acute lung injury or in other forms of pulmonary fibrosis. Angiogenesis may also contribute to growth of the synovial pannus in rheumatoid arthritis. Interposition of expanded, innervated synovium between articulating surfaces may contribute to pain on movement. In each of these situations, the expanded tissue may impair function.
  • the angiogenic growth factors bind to specific receptors located on the endothelial cells of nearby pre-existing blood vessels. Once growth factors bind to their receptors, the endothelial cells are activated and begin to produce enzymes and other molecules that dissolve tiny holes in the sheath-like basement membrane that surrounds existing blood vessels. The endothelial cells begin to divide and proliferate, and they migrate through the holes of the existing vessel towards the diseased tissue or tumour. Specialized adhesion molecules or integrins (avb3, avb ⁇ ) help to pull the new blood vessels forward. Additional enzymes, termed matrix metalloproteinases (MMP), are produced and dissolve the tissue in front of the sprouting vessel tip in order to accommodate it.
  • MMP matrix metalloproteinases
  • the tissue As the vessel extends, the tissue is remoulded around the vessel. Sprouting endothelial cells roll up to form a blood vessel tube and individual blood vessel tubes connect to form blood vessel loops that can circulate blood.
  • the newly formed blood vessel tubes are stabilized by smooth muscle cells, pericytes, fibroblasts, and glial cells that provide structural support, permitting blood flow to begin.
  • VEGF is a specific angiogenesis growth factor that binds to receptors on blood vessels and stimulates the formation of new blood vessels.
  • VEGF is a potent inducer of both endothelial cell proliferation and migration, and its biologic activities are largely specific for endothelial and vascular smooth muscle cells.
  • bFGF basic fibroblast growth factor
  • high levels of VEGF are not present in early surgical wounds. Rather, VEGF levels peak seven days after the wound is created, at which point VEGF appears to be a major stimulus for sustained induction of blood vessel growth and high levels of PDGF have been shown.
  • bFGF basic fibroblast growth factor
  • VEGF levels peak seven days after the wound is created, at which point VEGF appears to be a major stimulus for sustained induction of blood vessel growth and high levels of PDGF have been shown.
  • Anti-VEGF agents inhibit the action of VEGF.
  • bevacizumab is a recombinant humanized monoclonal IgGI antibody that binds to and inhibits the biologic activity of human VEGF in in vitro and in vivo assay systems by preventing binding of VEGF with its receptor on the surface of vascular endothelial cells, thus preventing endothelial cell proliferation and new vessel 'ifolfflStieJn ' SBlv ⁇ c ⁇ iijifliab contains human framework regions and the complementarity- determining regions of a murine antibody that binds to VEGF; it has a molecular weight of about 149 kilodaltons.
  • Bevacizumab by binding to VEGF, blocks VEGF from binding to receptors and thus blocks angiogenesis.
  • Bevacizumab is typically administered by intravenous infusion, diluted in 0.9% sodium chloride for injection from a 25 mg/ml preparation, for treatment of colorectal cancer.
  • Ranibizumab is a derivative of the full-length antibody bevacizumab (Fab fragment), and is further modified to increase its affinity for VEGF. Both bevacizumab and ranibizumab bind all biologically active isoforms and proteolytic fragments of VEGF, but there are differences. Monovalent binding of a Fab fragment such as ranibizumab to its target antigen would not force the target to dimerize, and hence is useful to manipulate cell receptor function, but its effective antigen binding capacity is lower than its full antibody counterpart.
  • VEGF which is the desired target, is a soluble factor and not a cellular receptor.
  • Bevacizumab has also been "humanized” to decrease any antigenic effect it may have on the patient, and bevacizumab has a higher molecular weight; this full-length antibody likely will not penetrate the retina to the same extent as the lower molecular weight fragment ranibizumab.
  • the increased size of bevacizumab may decrease its clearance rate from the site of action.
  • Sunitinib maleate is an orally bioavailable indolinone with potential antineoplastic activity. It blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.
  • This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor for tyrosine kinase expressed by some leukemic cells (NCI04).
  • a systemic dose for cancer treatment is between 12.5 mg/day to 50 mg/day.
  • MV n ⁇ . ⁇ / '' ' " AMm TM 1on 3g.7 -tfc1 IP-a. vailable anti-inflammatory agents many have a target of action to block or ameliorate the actions of pro-inflammatory signals, such as histamine and cytokines. Although this provides some relief from the harmful effects of inflammation, it does not address the cause of the problem.
  • Leukocytes and macrophages which release pro-inflammatory factors into affected areas, are allowed access to the inflamed tissue following new blood vessel formation.
  • the invention described herein may include one or more range of values (eg size, concentration etc).
  • a range of values will be understood to include all values within the range, including the values defining the range, and values adjacent to the range which lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range.
  • "foW ⁇ ] ⁇ ' -iWb ⁇ ' gHoif this specification, unless the context requires otherwise, the word “comprise” or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. It is also noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as “comprises”, “comprised”, “comprising” and the like can have the meaning attributed to it in U.S. Patent law.
  • a method for treating (eg controlling, ameliorating, or reducing), or preventing, in a patient, an inflammatory ailment.
  • a patient is given an anti-vascular endothelial growth factor (VEGF) agent to treat or prevent the inflammatory ailment.
  • VEGF anti-vascular endothelial growth factor
  • the invention also extends to a therapeutic method comprising the step of: providing to at least one inflammatory tissue in a patient a formulation comprising a therapeutically effective amount of an anti-VEGF agent, wherein the formulation ameliorates inflammation in the absence of angiogenesis.
  • the invention extends to an ocular prophylaxis or treatment method comprising the step of: ocularly providing to a patient, having or at risk for developing an ocular inflammatory ailment, a formulation comprising an anti-VEGF agent under conditions sufficient to ameliorate a cause and/or effect of fluid leakage in the eye.
  • the invention also extends to the use of an anti-vascular endothelial growth factor (VEGF) agent in the manufacture of a medicament to treat or prevent the inflammatory ailment. It extends to the use of a therapeutically effective amount of an anti-VEGF agent in the manufacture of a medicament to treat at least one inflammatory tissue in a patient wherein the formulation ameliorates inflammation in the absence of angiogenesis. Further, it extends to the use of an anti-VEGF agent in the manufacture of a medicament for prophylaxis or treatment of a patient having or at risk for developing an ocular inflammatory ailment. 10020].
  • VEGF anti-vascular endothelial growth factor
  • Aihti-VE ⁇ F::' agents include but are not limited to bevacizumab (rhuMab VEGF, Avastin®, Genentech, South San Francisco CA), ranibizumab (rhuFAb V2, Lucentis®, Genentech), pegaptanib (such as pegaptanib sodium ie Macugen ® , Eyetech Pharmaceuticals, New York NY) 1 sunitinib maleate (Sutent®, Pfizer, Groton CT), TNP470, integrin av antagonists, 2-methoxyestradiol, paclitaxel, or P38 mitogen activated protein kinase inhibitors.
  • bevacizumab rhuMab VEGF, Avastin®, Genentech, South San Francisco CA
  • ranibizumab rhuFAb V2, Lucentis®, Genentech
  • pegaptanib such as pegaptanib sodium ie Macugen ® ,
  • Anti-VEGF siRNA (short double-stranded RNA to trigger RNA interference and thereby impair VEGF synthesis) may also be used as an anti-VEGF agent.
  • the method is used to treat or prevent ocular inflammation. Ocular inflammation may be associated with underlying systemic disease or autoimmunity, or may occur as a direct result of ocular trauma or infectious agents (bacterial, viral, fungal, etc.).
  • the anti-VEGF agent is administered to a patient either alone or with one or more agent(s) known to one skilled in the art under the classification of anti-inflammatory agents, to treat or prevent an inflammatory ailment.
  • Anti-inflammatory agents include, but are not limited to, steroids, anti-prostaglandins, matrix metalloproteinase inhibitors, non-steroidal anti-inflammatory drugs (NSAIDS), macrolides, anti-proliferative agents, anti-cancer agents, etc.
  • the method is used to treat or prevent inflammation using an anti-VEGF agent such as bevacizumab alone.
  • the method is employed to treat or prevent an inflammatory ailment using an anti-VEGF agent such as bevacizumab in combination with at least another anti-inflammatory agent.
  • an anti-VEGF agent such as bevacizumab in combination with at least another anti-inflammatory agent.
  • the method may be used to treat or prevent an inflammatory ailment at any stage, even early stage inflammation before occurrence of an angiogenic component.
  • the method treats or prevents inflammation, and counteracts the action of angiogenic agents such as VEGF on the permeability of a vessel wall, thereby reducing or preventing the resulting tissue damage due to fluid leakage from the vessel (extravasation).
  • angiogenic agents such as VEGF
  • the method is applicable to any tissue or site in the body, and to any cause of inflammation such as immune disease including autoimmune disease, viral and/or bacterial infection, trauma including surgical trauma, etc.
  • sunitinib maleate may be used to ameliorate (e.g., reduce, prevent, slow, etc.) age related macular degeneration (AMD), either alone or in combination with PDT or laser coagulation therapy (e.g., scatter threshold laser coagulation, etc.) (such therapies are described in U.S. Patent No. 6,942,655, which is expressly incorporated by reference herein in its entirety).
  • AMD age related macular degeneration
  • Sunitinib maleate, alone or in combination with such therapies is administered to improve vision, maintain vision, or reduce loss of visual acuity in a patient having or at risk for developing AMD. By reducing, slowing, or preventing its onset or progression, it thus reduces effects of AMD.
  • the invention also extends to the use of sunitinib maleate in the manufacture of a medicament to treat or prevent AMD, either alone or in combination with PDT or laser coagulation therapy.
  • Methods described herein may be used to control, reduce, or prevent cell or tissue damage resultant from an inflammatory ailment in or in close proximity to the brain or eye.
  • Figure 1 is a schematic cross-sectional view of a mammalian eye 10 showing the anterior chamber 12, cornea 14, conjunctiva 16, iris 18, optic nerve 20, sclera 22, macula lutea 24, lens 26, retina 28 and choroid 30.
  • Figure 2 is an enlarged diagrammatic illustration of the circled area 2 in Figure 1 showing detailed retinal and choroids structures.
  • Figure 4 is a photograph of a representative bevacizumab-treated eye.
  • Figure 5 is a photograph of a representative control-treated eye. ! 'f003 ⁇ •• ' '' Flgdre- "8 ; !;: ts a micrograph of a control eye histology (cornea with neovascularization and moderate inflammation).
  • Figure 7 is a micrograph of a treated eye histology (skip areas of vascularization alternating with clear stroma)
  • Figure 8 illustrates the effects of corticosteroids with or without bevacizumab on VEGF R1 expression on CECs. Unstimufated cells were not stimulated or treated. Untreated and all other treatment groups were stimulated with PMA and treated as designated on the x-axis one day after plating. Flow cytometric analysis was performed after 3 days in culture. Results are expressed as means ⁇ SEM. Statistical significances are discussed in the text.
  • the invention concerns methods for treating or preventing, in a patient, an inflammatory ailment using at least an anti-vascular endothelial growth factor (VEGF) agent.
  • VEGF anti-vascular endothelial growth factor
  • the invention also extends to a therapeutic method comprising the step of: providing to at least one inflammatory tissue in a patient a formulation comprising a therapeutically effective amount of an anti-VEGF agent, wherein the method ameliorates inflammation in the absence of angiogenesis.
  • inflammation and angiogenesis can occur independently and administration of anti-VEGF agents such as bevacizumab, either alone or to supplement known anti-inflammatory agents, ameliorates both inflammation without an angiogenic component (earlier stage inflammation), and inflammation that has progressed to an angiogenic component (later stage inflammation).
  • Coexistence of inflammation and angiogenesis may lead to more severe, damaging, and persistent inflammation.
  • pfllf • ' ' Furt ⁇ i ef iffeFinvention extends to an ocular prophylaxis or treatment method comprising the step of: ocularly providing to a patient having or at risk for developing an ocular inflammatory ailment a formulation comprising an anti-VEGF agent under conditions sufficient to ameliorate a cause and/or effect of fluid leakage in the eye.
  • the invention also extends to the use of an anti-vascular endothelial growth factor (VEGF) agent in the manufacture of a medicament to treat or prevent the inflammatory ailment. It extends to the use of a therapeutically effective amount of an anti-VEGF agent in the manufacture of a medicament to treat at least one inflammatory tissue in a patient wherein the formulation ameliorates inflammation in the absence of angiogenesis. Further, it extends to the use of an anti-VEGF agent in the manufacture of a medicament for prophylaxis or treatment of a patient having or at risk for developing an ocular inflammatory ailment.
  • VEGF anti-vascular endothelial growth factor
  • inflammatory ailment will be understood to include inflammatory states, responses and disorders. It includes inflammation, an antiinflammatory response, and/or effects of an anti-inflammatory response.
  • the inventive method administers to a patient one or a combination of anti-VEGF agent(s) to treat or prevent an inflammatory ailment, and thus to control, reduce or prevent an inflammatory response or ameliorate the effects of an inflammatory response.
  • bevacizumab, ranibizumab or pegaptanib is used to enhance reabsorption of inflammatory exudates. Decreasing the level of exudates in the eye reduces the inflammatory process and the ensuing hyper-permeable state that occurs with allergies, infection, responses to ocular photodynamic therapy (PDT) and laser treatments, after ocular surgery or trauma, etc.
  • PDT ocular photodynamic therapy
  • the anti-VEGF agent is administered to ameliorate an inflammatory process without an angiogenic component.
  • Many inflammatory processes such as early stage inflammation, are not associated with the formation of new blood vessels. Examples include, but are not limited to, inflammatory diseases of the central nervous system (brain and spinal cord) such as abscess, meningitis, encephalitis, vasculitis, and conditions resulting in cerebral edema; inflammatory diseases of the eye (uveitis, subsequently discussed), macular edema, and others known to one skilled in the art.
  • the anti-VEGF agent(s) is administered to ameliorate scarring and adhesions that are a part of the inflammatory process. Adhesions are bands of scar tissue that bind two internal body surfaces.
  • adhesions are an inflammatory response to tissue damage, and occur as a normal part of any healing process.
  • adhesions frequently occur during the post-surgical healing process during which tissues have experienced mechanical trauma.
  • adverse effects can occur when internal surfaces bind, and adhesions may persist even after the original trauma has healed.
  • Surgery to repair adhesions itself results in recurrent or additional adhesions.
  • the presence of adhesions may also complicate surgical procedures, for example, ocular conjunctival adhesions may complicate subsequent glaucoma surgery.
  • Adhesions can occur following any type of trauma or surgery, including but not limited to ocular surgery.
  • ocular surgery that may result in adhesions include glaucoma filtration operations (i.e., iridencleisis and trephination, pressure control valves), extraocular muscle surgery, diathermy or scleral buckling surgery for retinal detachment, and vitreous surgery.
  • ocular trauma include penetrating ocular injuries, intraocular foreign body, procedures such as PDT, scatter laser threshold coagulation, refractive surgery, and blunt trauma.
  • anti-VEGF agents are used in the method to ameliorate disorders with both a vascular proliferative component and a scarring component.
  • the invention may be used in patients with the ocular disease pterygia. In these patients, fibrovascular proliferation results in scarring of the conjunctiva.
  • the anti-VEGF agent(s) is administered to treat or prevent and inflammatory ailment associated with uveal tissues (uveitis, an inflammation of tissues in the middle layer of the eye, mainly the iris (iritis) and the ciliary body).
  • Ocular inflammation may be associated with underlying systemic disease or autoimmunity, or may occur as a direct result of ocular trauma or infectious agents (bacterial, viral, fungal, etc.). Inflammatory reactions in adjacent tissues, e.g., keratitis, can induce a secondary uveitis.
  • uveitis an inflammation of tissues in the middle layer of the eye, mainly the iris (iritis) and the ciliary body.
  • Ocular inflammation may be associated with underlying systemic disease or autoimmunity, or may occur as a direct result of ocular trauma or infectious agents (bacterial, viral, fungal, etc.).
  • Inflammatory reactions in adjacent tissues, e.g., keratitis can induce a secondary
  • Uveitis presents with ocular pain, photophobia and hyperlacrimation, with decreased visual acuity ranging from mild blur to significant vision loss.
  • Hallmark signs of anterior uveitis are cells and flare in the anterior chamber. If the anterior chamber reaction is significant, small gray to brown endothelial deposits known as keratic precipitates may arise, leading to endothelial cell dysfunction and corneal edema. There may be adhesions to the lens capsule (posterior synechia) or the peripheral cornea (anterior synechia). Granulomatous nodules may appear on the surface of the iris stroma.
  • Intraocular pressure is initially reduced due to secretory hypotony of the ciliary body but, as the reaction persists, inflammatory by-products may accumulate in the trabeculum. If this debris builds significantly, and if the ciliary body resumes its normal secretory output, the pressure may rise sharply, resulting in a secondary uveitic glaucoma.
  • scarring and adhesions in areas of the body other than the eye may be treated with the inventive method.
  • Examples include adhesions associated with cardiac surgery (e.g., adhesions in the pericardial space), pulmonary surgery (e.g., in the peripleural space), abdominal surgery (e.g., appendectomy, gastric bypass surgery), gynaecological surgery (e.g., episiotomy, Caesarean section, hysterectomy), any type of laparoscopy or laparotomy surgery, reconstructive surgery (cosmetic or therapeutic), organ removal (partial or complete), etc. "[0OS*»3.
  • the inventive method comprises the step of administering to a patient an anti-inflammatory agent simultaneously or concomitantly with an anti-VEGF agent such as bevacizumab to control, reduce, or prevent an inflammatory ailment.
  • an anti-VEGF agent such as bevacizumab
  • Other anti-VEGF agents such as Lucentis ® , Macugen ® , Sutent ® , geldanamycin, etc. may be included.
  • the method is used to treat or prevent inflammation using bevacizumab alone.
  • Bevacizumab at a dose of 5 mg/0.1 ml has been found not to be toxic.
  • the dose of bevacizumab ranges between about 0.01 mg/0.1 ml to about 5 mg/0.1 ml. Accordingly the administered dose of bevacizumab is preferably less than about 5 mg/0.1 ml. In another embodiment, the administered dose of bevacizumab ranges from about 0.1 mg/ml to about 50 mg/ml.
  • the dose of bevacizumab administered systemically ranges from about 0.05 mg/ml to about 5 mg/ml.
  • the dose of bevacizumab administered intraocularly e.g., intravitreally
  • the dose of bevacizumab administered topically to the eye is up to 5 mg/ml, and in another embodiment it may be higher. While these doses recite bevacizumab, one skilled in the art will appreciate that they may be used with other anti-VEGF agents, and that doses for a specific agent may be determined empirically, by patient disease severity, other patient variables, etc!
  • the method is used to treat or prevent inflammation using ranibizumab or pegaptanib.
  • ranibizumab (Lucentis ® )
  • the administered dose of ranibizumab is either about 300 or about 500 microgram doses .
  • pegaptanib e.g. Macugen ®
  • pegaptanib e.g. Macugen ®
  • the method may be used to treat or prevent an inflammatory ailment in any tissue including, but not limited to, eye (e.g., to ameliorate conjunctivitis (inflammation of the conjunctivae, the mucous membranes covering the sclera and inner eyelid), that may be associated with bacterial, viral, or Chlamydia infections, allergies, or susceptibility to irritants such as chemicals, smoke, etc.), lung (e.g., to ameliorate interstitial lung disease, inflammation of the interstitium (tissue between the air sacs in ⁇ h'y !
  • the method may be used on patients with inflammation and/or inflammatory processes from any cause, including but not limited to autoimmune diseases, diseases with an immune component, ischemic diseases, diabetes, age related macular degeneration, retinitis pigmentosa, infectious diseases, allergen-induced inflammation, other degenerative diseases, etc.
  • the anti-VEGF agent is administered to a patient either alone or with one or more agent(s) known to one skilled in the art under the classification of anti-inflammatory agents, to treat or prevent an inflammatory ailment.
  • Anti-inflammatory agents include, but are not limited to, steroids, anti-prostaglandins, matrix metalloproteinase inhibitors, non-steroidal anti-inflammatory drugs (NSAIDS), macrolides, anti-proliferative agents, anti-cancer agents, etc.
  • anti-inflammatory agents recognized by one skilled in the art include, but are not limited to, the following: a. colchicine; b._ a steroid such as triamcinolone (Aristocort®; Kenalog ® ),.
  • anecortave acetate (Retaane ® , Alcon), betamethasone (Celestone ® ), budesonide cortisone, dexamethasone (Decadron-LA®; Decadron® phosphate; Maxidex ® and Tobradex ® (Alcon)), hydrocortisone methylprednisolone (Depo-Medrol ® , SoIu- Medrol ® ), prednisolone (prednisolone acetate, e.g., Pred Forte ® (Aliergan), Econopred and Econopred Plus ® (Alcon), AK-Tate® (Akorn), Pred Mild ® (Aliergan), prednisone sodium phosphate (Inflamase Mild and lnflamase Forte ® (Ciba), Metreton ® (Schering), AK-Pred ® (Akorn)), fluo
  • an anti-prostaglandin such as indomethacin
  • ketorolac tromethamine (( ⁇ )-5- benzoyl-2,3-dihydro-1 H-pyrrolizine-1-carboxylic acid, a compound with 2-amino- ,3-propanediol (1 :1) (Acular ® Allegan), Ocufen ® (flurbiprofen sodium 0.03%), meclofenamate, fluorbiprofen, and the pyrrolo-pyrrole group of non-steroidal anti-inflammatory drugs; d.
  • ketorolac tromethamine (( ⁇ )-5- benzoyl-2,3-dihydro-1 H-pyrrolizine-1-carboxylic acid, a compound with 2-amino- ,3-propanediol (1 :1) (Acular ® Allegan), Ocufen ® (flurbiprofen sodium 0.03%), meclofenamate,
  • a macrolide such as sirolimus (rapamycin), pimecrolimus, tacrolimus (FK506), cyclosporine (Arrestase), everolimus 40-O-(2-hydroxymethylenrapamycin), ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, lincosamide, biolimus, ABT- 578 (methylrapamycin), and derivatives of rapamycin such as temsirolimus (CCI- 779, Wyeth) and AP23573 (Ariad); e.
  • a non-steroidal anti-inflammatory drug such as derivatives of acetic acid (e.g. diclofenac and ketorolac (Toradol ® , Voltaren ® , Voltaren-XR ® , Cataflam ® )), salicylate (e.g., aspirin, Ecotrin ® ), proprionic acid (e.g., ibuprofen (Advil ® , Motrin ® , Medipren ® , Nuprin ® )), acetaminophen (Tylenol ® ), aniline (e.g., aminophenolacetaminophen, pyrazole (e.g., phenylbutazone), N-arylanthranilic acid (fenamates) (e.g., meclofenamate), indole (e.g., indomethacin (Indocin ® , Indocin-SR ® )), oxicam (e.g.
  • MMP inhibitor such as doxycycline, TIMP-1 , TIMP-2, TIMP-3, TIMP-4; MMP1 , MMP2, MMP3, Batimastat (BB-94), TAPI-2,10-phenanthroline, and marimastat.
  • the formulation may also contain anti-PDGF compound(s) such as imatinib mesylate (Gleevec ® ), sunitinib malate (Sutent ® ) which has anti-PDGF activity in addition to anti-VEGF activity, and/or anti-leukotriene(s) such as genleuton, montelukast, cinalukast, zafirlukast, pranlukast, zileuton, BAYX1005, LY171883, and MK-571 to account for the involvement of factors besides VEGF in neovascularization.
  • anti-PDGF compound(s) such as imatinib mesylate (Gleevec ® ), sunitinib malate (Sutent ® ) which has anti-PDGF activity in addition to anti-VEGF activity, and/or anti-leukotriene(s) such as genleuton, montelukast, cinaluk
  • the formulation may additionally contain other agents including, but not limited to, transforming growth factor ⁇ (TGF ⁇ ), interleukin-10 (IL-10), aspirin, a vitamin, and/or an antineoplastic agent.
  • TGF ⁇ transforming growth factor ⁇
  • IL-10 interleukin-10
  • aspirin a vitamin
  • antineoplastic agent e.g., transforming growth factor ⁇ (TGF ⁇ ), interleukin-10 (IL-10), aspirin, a vitamin, and/or an antineoplastic agent.
  • compositions prepared according to the present invention may be prepared in combination with a glucocorticoid (e.g. prednisolone, prednisone), an oestrogen (e.g. oestrodiol), an androgen (e.g. testosterone) retinoic acid derivatives (e.g. 9-cis-retinoic acid, 13-trans- retinoic acid, all-trans retinoic acid), a vitamin D derivative (e.g.
  • a glucocorticoid e.g. prednisolone, prednisone
  • an oestrogen e.g. oestrodiol
  • an androgen e.g. testosterone
  • retinoic acid derivatives e.g. 9-cis-retinoic acid, 13-trans- retinoic acid, all-trans retinoic acid
  • vitamin D derivative e.g.
  • calcipotriol calcipotriene
  • a non-steroidal anti-inflammatory agent a vitamin D derivative, an anti- infective agent, a protein kinase C inhibitor, a MAP kinase inhibitor, an anti-apoptotic agent, a growth factor, a nutrient vitamin, an unsaturated fatty acid, and/or ocular anti- infective agents, for the treatment of the ophthalmic disorders set forth herein.
  • a mixture of these agents may be used.
  • the formulations may include ocular anti-infective agents such as penicillins (ampicillin, aziocillin, carbenicillin, dicloxacillin, methicillin, nafcillin, oxacillin, penicillin G, piperacillin, and ticarcillin), cephalosporins (cefamandole, cefazolin, cefotaxime, cefsulodin, ceftazidime, ceftriaxone, cephalothin, and moxalactam), aminoglycosides (amikacin, gentamicin, netilmicin, tobramycin, and neomycin), miscellaneous agents such as aztreonam, bacitracin, ciprofloxacin, clindamycin, chloramphenicol, cotrimoxazole, fusidic acid, imipenem, metronidazole, t
  • penicillins ampicillin, aziocillin, carbenicillin,
  • an anti-VEGF agent(s) is administered with an anti-infiammatory agent
  • an effective amount of the anti-inflammatory agent is administered to a patient at a standard dose known to one skilled in the art.
  • prednisone is administered for a systemic dose in the range between about 5 mg to about 100 mg daily.
  • Solu-medrol® is administered intravenously in a single dose of about 1 mg.
  • the prostaglandin antagonist will be administered in a concentration sufficient to result in a prostaglandin inhibitory effect.
  • anti- prostaglandins such as flurbiprofen may be administered at a concentration in the range of about 0.001 % w/v to about 0.5% w/v .
  • OCUFEN® flurbiprofen sodium 0.03% (Allergan), sodium ( ⁇ )-2-(2-fluoro-4-biphenylyl)-propionate dihydrate) 0.03% may be administered at a concentration ranging from about 0.003% ⁇ /w to about 0.3% w/w .
  • Anti-prostaglandins other than flurbiprofen may be included.
  • the anti- prostaglandins may be administered at the doses and by the methods previously described, and include indomethacin, ketorolac, tromethamine 0.5% ((+) ⁇ 5-benzoyl-2,3- dihydro-1 H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)- 1 ,3-propanediol (1 :1) (ACULAR ® Allegan, Irvine CA), meclofenamate, flurbiprofen, and compounds in the pyrrolo-pyrrole group of non-steroidal anti-inflammatory drugs (NSAIDs).
  • ACULAR® may be administered at a concentration ranging from about 0.003% w/w to about 0.3% w/w . In one embodiment, the concentration of ACULAR® is about 0.03% w/w
  • the anti-VEGF agent employed in the method is formulated with a macrolide
  • the macrolide will be present in an amount sufficient to induce a therapeutic effect.
  • it might be administered in a concentration ranging from about 20 ⁇ g/ml to about 200 ⁇ g/ml (about 0.002%w/v to about 0.02%w/v).
  • the anti-VEGF agent employed in the method is formulated with a MMP inhibitor
  • the inhibitor will be present in an amount sufficient to inhibit MMPs and prevent pathogenic tissue destruction.
  • concentration of doxycycline employed in this form of the invention will range from 0.01 ⁇ g/ml to about 30 mg/ml.
  • i ⁇ VJiolri ⁇ spelsiffclffyf ! 'iufoxycycline concentrations will range from about 0.05 mg/ml to about 1 mg/ml.
  • doxycycline concentrations will range from about 0.05 mg/ml to about 10 mg/ml.
  • doxycycline concentrations can range from about 1 mg/ml to about 20 mg/ml.
  • the formulations employed in the method may be administered by a variety of routes including enteral, parenteral, and ocular routes such as intravitreal injection, subconjunctival injection, retrobulbar injection, topical, intravenously, orally, ocularly, etc.
  • routes of administration may vary due to factors such as agent solubility, patient needs, dose required, etc.
  • the active agent may be fast-acting, slow acting, or both.
  • formulation may be formulated for delayed and/or extended release to provide effects over a longer period of time.
  • methods of the invention are used to treat ocular inflammatory ailments and as such the formulations employed in the methods are administered by an ocular route, such as topical, subconjunctival, sub-Tenon, intraocular, etc. to the extent that the invention concerns the use of the above agents in the treatment of ocular inflammatory ailments doses for topical and sub-conjunctival administration of the above agents, as well as intravitreal dose and vitreous half-life may be found in Intravitreal Surgery Principles and Practice, Peyman G A and Shulman, J Eds., 2nd edition, 1994, Appleton-Longe, the relevant sections of which are expressly incorporated by reference herein.
  • any of the formulations of the invention will dwell in a cellular environment will depend, inter alia, on such factors as the pharmacological properties of the compounds employed in the formulation, the concentration of the compound employed, the bioavailability of the compound, the inflammatory ailment to be treated, the mode of administration and the preferred longevity of the treatment. Where that balance is struck will often depend on the longevity of the effect required and the ailment being treated.
  • Formulations prepared according to the invention will preferably have dwell times from hours to many months and possibly years, although the latter time period requires special delivery systems to attain such a duration.
  • the formulations described herein will have a dwell time of hours (i.e. 1 to 24 hours), days (i.e. 1 , 2, 3, 4, 5, 6 or 7 days) or weeks (i.e. 1 , 2, 3, 4 weeks).
  • the formulation will have a dwell time of at I f ⁇ aSI SS few ; M6n!HslsIch as, 1 month, 2 months, 3 months, with dwell times of greater than 4, 5, 6, 7 to 12 months being achievable.
  • the formulations used in the methods of the invention may contain other agents.
  • the formulations may include a physiological saline solution as a carrier vehicle.
  • the pH of the formulation may be maintained at a substantially neutral pH (for example, about 7.4, in the range of about 6.5 to about 7.4, etc.) with an appropriate buffer system as known to one skilled in the art (for example, acetate buffers, citrate buffers, phosphate buffers, borate buffers).
  • the formulation may additionally include at least a pharmaceutically acceptable additive (such as a diluent, carrier, adjunct, excipient or non-toxic, non- therapeutic, non-immunogenic stabilizers and the like).
  • a pharmaceutically acceptable additive such as a diluent, carrier, adjunct, excipient or non-toxic, non- therapeutic, non-immunogenic stabilizers and the like.
  • the pharmaceutically acceptable additive should be ophthalmologically acceptable when used to treat ocular inflammatory ailments. More preferably the formulation will be compatible with the vitreous, and should not leave any vision impairing residue in the eye. Desirably, any pharmaceutically acceptable additive used in the formulation may preferably be suited to the delivery of the pharmaceutical formulation as an intravitreal depot injection.
  • any diluent used in the preparation of the pharmaceutically acceptable formulation is preferably selected so as not to unduly affect the biological activity of the formulation.
  • diluents which are especially useful for formulation preparation are water, saline, organic or inorganic salt solutions, Ringer's solution, dextrose solution, and Hank's solution.
  • solutions may be prepared using a physiological saline solution as a vehicle.
  • the pH of an ophthalmic solution may be maintained at a substantially neutral pH (for example, about 7.4, in the range of about 6.5 to about 7.4, etc.) with an appropriate buffer system as known to one skilled in the art (for example, acetate buffers, citrate buffers, phosphate buffers, borate buffers).
  • the formulations used in the invention may also contain pharmaceutically acceptable excipients known to one skilled in the art such as preservatives, stabilizers, surfactants, chelating agents, antioxidants such as vitamin C, etc.
  • Preservatives include, but are not limited to, benzalkonium chloride, chlorobutanol, ' pfie'iny ' irife'rcuric acetate and phenylmercuric nitrate.
  • a surfactant may be Tween 80.
  • Other vehicles that may be used include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose, purified water, etc.
  • Tonicity adjustors may be included, for example, sodium chloride, potassium chloride, mannitol, glycerin, etc.
  • Antioxidants include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, butylated hydroxyt ⁇ luene, etc.
  • the pharmaceutical formulation may include additives such as other buffers, diluents, carriers, adjuvants or excipients.
  • Any pharmacologically acceptable buffer suitable for application to the eye may be used, e.g., tris or phosphate buffers.
  • Other agents may be employed in the formulation for a variety of purposes. For example, buffering agents, preservatives, co-solvents, surfactants, oils, humectants, emollients, chelating agents, stabilizers or antioxidants may be employed.
  • Water soluble preservatives which may be employed include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, sodium bisulfate, phenylmercuric acetate, phenylmercuric nitrate, ethyl alcohol, methylparaben, polyvinyl alcohol, benzyl alcohol and phenylethyl alcohol.
  • a surfactant may be Tween 80.
  • Other vehicles that may be used include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose, purified water, etc.
  • Tonicity adjustors may be included, for example, sodium chloride, potassium chloride, mannitol, glycerin, etc.
  • Antioxidants include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, butylated hydroxytoluene, etc.
  • the indications, effective doses, formulations, contraindicatons, vendors etc, of the compounds in the formulations are available or are known to one skilled in the art.
  • These agents may be present in individual amounts of from about 0.001% to about 5% by weight and preferably about 0.01 % to about 2% by weight.
  • Suitable water soluble buffering agents that may be employed are sodium carbonate, sodium borate, sodium phosphate, sodium acetate, sodium bicarbonate, etc., as approved by the US FDA for the desired route of administration. These agents may be present in amounts sufficient to maintain a pH of the system of between about 2 to about 9 and preferably about 4 to about 8. As such the buffering agent may be as much as about 5% on a weight to weight basis of the total formulation.
  • Electrolytes such as, but not MiMi 4bf%6d ⁇ i ⁇ # l!' ehloride and potassium chloride may also be included in the formulation.
  • the formulation employed in the methods of the invention may be administered as a slow release formulation, with a carrier formulation such as microspheres, microcapsules, liposomes, etc., as an intravenous solution or suspension, or in an intraocular injection, as known to one skilled in the art.
  • a time-release drug delivery system may be administered intraocularly to result in sustained release of the agent over a period of time.
  • the formulation may be in the form of a vehicle, such as a micro- or macro-capsule or matrix of biocompatible polymers such as polycaprolactone, polyglycolic acid, polylactic acid, polyanhydrides, polylactide-co- glycolides, polyamino acids, polyethylene oxide, acrylic terminated polyethylene oxide, polyamides, polyethylenes, ⁇ olyacrylonitriles, polyphosphazenes, poly(ortho esters), sucrose acetate isobutyrate (SAIB), and other polymers such as those disclosed in U.S. Patent Nos.
  • biocompatible polymers such as polycaprolactone, polyglycolic acid, polylactic acid, polyanhydrides, polylactide-co- glycolides, polyamino acids, polyethylene oxide, acrylic terminated polyethylene oxide, polyamides, polyethylenes, ⁇ olyacrylonitriles, polyphosphazenes, poly(ortho esters), sucrose acetate isobutyrate (SAIB
  • lipids that may be formulated as microspheres or liposomes.
  • a microscopic or macroscopic formulation may be administered through a needle, or may be implanted by suturing within the eye, for example, within the lens capsule.
  • Delayed or extended release properties may be provided through various formulations of the vehicle (coated or uncoated microsphere, coated or Uncoated capsule, lipid or polymer components, unilamellar or multilamellar structure, and combinations of the above, etc.).
  • the formulation and loading of microspheres, microcapsules, liposomes, etc. and their ocular implantation are standard techniques known by one skilled in the art, for example, the use a ganciclovir sustained-release implant to treat cytomegalovirus retinitis, disclosed in Vitreoretinal Surgical Techniques, Peyman et al., Eds. (Martin Dunitz, London 2001 , chapter 45); Handbook of Pharmaceutical Controlled Release Technology, Wise, Ed.
  • a sustained release intraocular implant may be inserted through the pars plana for implantation in the vitreous cavity.
  • An intraocular injection may be into the vitreous (intravitreal), or under the conjunctiva (subconjunctival), or behind the eye (retrobulbar), or under the Capsule of Tenon (sub-Tenon), and may be in a depot form.
  • Other intraocular routes of administration ⁇ irfc. l ⁇ iij €icti ' ⁇ ff's ⁇ fei ind forms are also contemplated and are within the scope of the invention.
  • bevacizumab and/or other anti-VEGF agent(s) may be administered via a controlled release system (i.e., delayed release formulations and/or extended release formulations) such as polylactic or polyglycolic acid, silicone, hema, and/or polycaprolactone microspheres, microcapsules, microparticles, nanospheres, nanocapsules, nanoparticles, etc.
  • a slow release system may release about 10 ng anti-VEGF agent/day to about 50 ng anti-VEGF agent/day for an extended period.
  • Administration may be by any suitable route, and where more than one formulation or agent is to be administered, administration may be by the same route or by different routes, including enteral, parenteral, and ocular routes such as intravitreal injection, subconjunctival injection, retrobulbar injection, topical, etc.
  • the anti- VEGF agent (bevacizumab, sunitinib, etc.) may be topically administered to intact or compromised eyes, skin, mucous membranes, etc. to reduce scarring after trauma, surgery, radiation, burns, wounds, etc.
  • it may be locally administered to a site in a surgical field to ameliorate inflammation (e.g., adhesions, scarring, effusions) of pleura, epicardium, etc. after thoracic, cardiac, abdominal, etc. surgery.
  • inflammation e.g., adhesions, scarring, effusions
  • it may be administered intrathecal ⁇ (brain, spinal cord, etc.).
  • it may be administered by inhalation, for example, to ameliorate inflammation in the respiratory tract (nose, trachea, bronchi, lungs, etc.).
  • it may be instilled in a body cavity (ventricles, sinuses, bladder, etc.).
  • the anti-VEGF agent may be administered systemically (e.g., a single dose/week for one month, then monthly re-evaluation of need) or topically (e.g., from about 10 ng/ml to about 100 ng/ml), or intraocularly (e.g., from about 7 ng/ml to about 20 ⁇ g/ml).
  • the formulation may be administered by topical, subconjunctival, and intraocular routes or ocular implants.
  • the formulation is intraocularly injected, for example, into the vitreous.
  • the active Sgel ⁇ sftol ' ⁇ f BI3JPicentratecl to minimise the volume for injection.
  • a concentration less than about 20 mg/ml may be injected, and any amount may be effective depending upon the factors previously described.
  • a dose of less than 7 mg/ml is administered, with doses of less than 6 mg/ml, 5 mg/ml, 4 mg/ml 3 mg/ml, 2 mg/ml and 1 mg/ml being more preferred.
  • Sample concentrations include, but are not limited to, about 5 ⁇ g/ml to about 50 ⁇ g/ml; about 25 ⁇ g/ml to about 100 ⁇ g/ml; about 100 ⁇ g/ml to about 200 ⁇ g/ml; about 200 ⁇ g/ml to about 500 ⁇ g/ml; about 500 ⁇ g/ml to about 750 ⁇ g/ml; about 500 ⁇ g/ml up to i mg/ml; etc.
  • topical alcaine was applied to the ocular surface, followed by 5% povidone iodine.
  • a cotton-tipped applicator soaked in 4% lidocaine was then applied to the injection site, which was 4.0 mm posterior to the limbus in phakic eyes and 3.5 mm posterior to the limbus in pseudophakic eyes.
  • a 27-gauge needle was used for injection at the superior pars plana. Indirect ophthalmoscopy can be used to confirm proper intravitreal placement of the suspension.
  • a suitable style of syringe is, for example, sold under the name of Uniject TM manufactured by Becton Dickinson and Company.
  • the material is expelled through the needle into the eye by pressure applied to the sides of a pliable reservoir supplying the needle, rather than by a plunger.
  • the construction of the reservoir and needle forms a single unit.
  • Topical application of formulations of the invention may be as an in situ gellable aqueous formulation.
  • a formulation comprises a gelling agent in a concentration effective to promote gelling upon contact with the eye or with lacrimal fluid in the exterior of the eye.
  • Suitable gelling agents include, but are not limited to, thermosetting polymers such as tetra-substituted ethylene diamine block copolymers of ethylene oxide and propylene oxide (e.g., poloxamine); polycarbophil; and polysaccharides such as gellan, carrageenan (e.g., kappa-carrageenan and iota- carrageenan), chitosan and alginate gums.
  • in situ gellable as used herein embraces not only liquids of low viscosity that form gels upon contact with the eye or with lacrimal fluid in the exterior of the eye, but also more viscous liquids such as semi-fluid and thixotropic gels that exhibit substantially increased viscosity or gel stiffness upon administration to the eye.
  • SMeiid/Oan '' HKidlantageous to formulate a formulation of the invention as a gel to minimize loss of the formulation immediately upon administration, as a result, for example, of lacrimation caused by reflex blinking.
  • a therapeutically effective amount of the formulation of the invention is placed in an ophthalmological vehicle as is known in the art.
  • the amount of the therapeutic compound to be administered and the concentration of the compound in the topical formulations depend upon the diluent, delivery system or device selected, the clinical condition of the patient, the side effects and the stability of the compound in the formulation.
  • the physician employs the appropriate preparation containing the appropriate concentration of the therapeutic compound and selects the amount of formulation administered, depending upon clinical experience with the patient in question or with similar patients.
  • the active agents may be administered as a mixture, as an admixture, in the same formulation, in separate formulations, in extended release formulations, liposomes, microcapsules, or any of the previously described embodiments.
  • the formulation may be administered topically, or may be injected into the eye, or one active agent may be administered topically and the other agent(s) may be injected.
  • the method of the present invention may be performed alone, or in combination with one or more other therapies such as photodynamic therapy, laser treatment, or one or more biological or pharmaceutical treatments.
  • the invention resides in a method for reducing ocular irritation comprising the step of: administering to a patient a formulation as described above to a patient following corneal surgery (e.g., LASIK® surgery, photorefractive keratectomy (PRK), or other corneal procedures).
  • a formulation as described above to a patient following corneal surgery (e.g., LASIK® surgery, photorefractive keratectomy (PRK), or other corneal procedures).
  • i ⁇ JOUJPIIJ / ⁇ $ with the method an effective amount of anti-VEGF agent; either as the sole active agent, or with one or more other non-anti-inflammatory agents as previously described, is administered to a patient.
  • the formulations may contain other agents.
  • the indications, effective doses, formulations, contraindications, vendors, etc. of these are available or are known to one skilled in the art. It will be appreciated that the agents include pharmaceutically acceptable salts and derivatives.
  • an anti-VEGF agent such as bevacizumab
  • other agents such as an anti-PDGF agent, another anti-VEGF agent, etc.
  • PDT is frequently used to reduce or prevent damage from leaky vessels associated with age related macular degeneration and other diseases.
  • a series of PDT treatments is often performed with a cumulative effect that, over time, results in retinal damage which in some cases may be severe.
  • the present invention may obviate the need for PDT thus eliminating its associated damage.
  • Bevacizumab may be used to ameliorate (e.g., reduce, prevent, slow, etc.) corneal neovascularization.
  • a subsequent example demonstrated the efficacy of bevacizumab on corneal neovascularization that was chemically induced.
  • the invention is not so limited and is applicable to amelioration of corneal neovascularization resulting from other etiologies.
  • corneal transplant rejection mechanical trauma
  • corneal ulcers caused by any mechanism including microorganisms, conjunctivitis sicca, use of contact lenses, presence of a foreign body, pemphigus, Sjorgen's disease, and other autoimmune diseases of the cornea and/or sclera.
  • sunitinib maleate may be used to ameliorate (e.g., reduce, prevent, slow, etc.) age related macular degeneration (AMD), either alone or in combination with PDT or laser coagulation therapy (e.g., scatter threshold laser coagulation, etc.) (such therapies are described in U.S. Patent No. 6,942,655, which is expressly incorporated by reference herein in its entirety).
  • AMD age related macular degeneration
  • Sunitinib maleate, alone or in combination with such therapies is administered to improve vision, maintain vision, or reduce loss of visual acuity in a patient having or at risk for • ' ⁇ ' slowing, or preventing its onset or progression, it thus reduces effects of AMD.
  • a substantially non-toxic dose of sunitinib maleate is intraocularly administered. Because patients with early stage AMD may receive PDT, there may be cumulative inflammatory effects. Inflammation may result from an immune disease or reaction, including autoimmune diseases, or the presence of a foreign body or organism in the eye. It may be due to macular edema from any cause.
  • sunitinib maleate is administered as the sole agent. It may be administered orally at a dose ranging between about 12.5 mg/day to about 50 mg/day. It may be administered topically at a dose ranging between about 10 ng/ml to about 100 ng/ml. It may be administered intraocularly at a dose between about 7 ng/ml to about 20 ⁇ g/ml.
  • the agent may be formulated as a liquid, suspension (e.g., small particulates suspended in a liquid), etc. It will be appreciated that other formulations, including but not limited to emulsions, microspheres, liposomes, nanoparticles, nanospheres, etc. may also be delivered by the device.
  • the dose may be administered by a controlled release system, as previously described, formulated as known by one skilled in the art, to release about 10 ng/day to about 50 ng/day over several years.
  • the dose may be administered in any convenient volume (e.g. from about 0.1 ml to ⁇ about 0.5 ml).
  • doses for a- specific patient may be determined empirically, by disease severity, the presence of other pathologies, other patient variables such as age and gender, etc.
  • the individual using the inventive method may be at risk for developing AMD, may present with one or more symptoms of AMD, and/or may be already undergoing therapy for AMD using other therapies, either singly or in combination.
  • the method delays the onset or severity of the symptoms of AMD, improving visual acuity and/or preventing further vision loss, and/or reducing the need for retreatments.
  • the combination of anti-VEGF agents with other anti-inflammatory agents results in collective or synergistic action to reduce or halt disease progression.
  • the method achieves a synergistic effect when ocular phototherapy, for example, PDT, scatter threshold laser coagulation, other types of laser therapy, conjunction with sunitinib maleate.
  • the therapies damage the existing lesion of nascent vessels, and reduce the recurrence and slow the progression of additional new vessels.
  • the therapies may be administered in any sequence, that is, sunitinib maleate may be administered before or after PDT, etc. or they may be administered essentially simultaneously, as discussed in more detail below. In one embodiment, sunitinib maleate may be administered prior to laser treatment.
  • sunitinib maleate treatment will decrease existing subretinal exudates, rendering subsequent laser treatment more effective.
  • sunitinib maleate treatment will reduce subsequent hyperpermeability that results because of the release of VEGF as a consequence of laser procedures.
  • AMD is a pathological, progressive age-related degeneration in the macula lutea 24 of the retina 28
  • FIG. 1 is a schematic cross-sectional view of a mammalian eye 10 showing the anterior chamber 12, cornea 14, conjunctiva 16, iris 18, optic nerve 20, sclera 22, macula lutea 24, lens 26, retina 28 and choroid 30.
  • AMD is the most common cause of legal blindness among individuals over the age of 60, with an incidence ranging from 11% to 18.5% in individuals over the age of 85. In the United States, AMD affects roughly 3.6 million individuals, with more than 200,000 new cases developing annually.
  • FIG. 2 is an enlarged diagrammatic illustration of the circled area 2 in FIG. 1 showing detailed retinal and choroidal structures.
  • an outer segment of photoreceptor cells 32 including rods and cones, a subretinal space 34, and a layer of retinal pigment epithelium (RPE) 36.
  • RPE retinal pigment epithelium
  • retinal blood vessels 38 including capillaries, have walls or membranes 40 that contain no fenestrations or openings.
  • the large choroidal vessels 42 similarly have walls 44 that contain no fenestrations but the choriocapillaries 46 have walls that contain fenestrations 48.
  • the RPE cells are lost.
  • neovascular tissue 52 In exudative AMD, a lesion of subretinal neovascular tissue 52 develops in the choroid 30.
  • the neovascular tissue 52 penetrates the RPE 36 and subretinal space 34, and extends into the area containing photoreceptor cells 32.
  • the neovascular tissue 52 has membranes or walls 54 that are altered in having tertg ⁇ ati ⁇ rt&/5 ⁇ ;.wM ⁇ h permit fluid leakage into spaces surrounding photoreceptor cells 32, the subretinal space 34, and the RPE 36.
  • One type of AMD results in proliferation of new blood vessels in the subretinal area, typically the choroid.
  • both the large blood vessels and the capillaries have intact vessel walls.
  • the large vessels In the normal choroid, the large vessels have intact vessel walls, but the capillaries have fenestrations or openings in their walls.
  • new blood vessels proliferate from the choriocapillaries through defects in Bruch's membrane beneath or on top of retinal pigment epithelium (RPE), and form vascular membranes.
  • RPE retinal pigment epithelium
  • choroidal neovascularizations new vessels in the choroid
  • the resulting choroidal neovascularizations occur in about 8-10% of all patients with AMD, and are also seen in patients with pathologic myopia and presumed ocular histoplasmosis syndrome, as well as other idiopathic conditions.
  • any endogenous or exogenous fluid contained in these vessels will leak outside of the vessels and accumulate in the surrounding spaces.
  • This accumulation of fluid can result in serous and hemorrhagic detachment of the RPE and neurosensory retina, and can lead to scarring in this area (fibrous deform scarring), resulting in decreased vision or even loss of vision.
  • AMD neovascular, exudative, or occult AMD
  • Therapies to prevent this form of AMD are directed to slowing or stopping the formation or proliferation of new vessels in the choroid 30.
  • therapies to treat neovascular AMD are directed to at least partially damaging or destroy existing neovascular tissue 52, and/or interfering with its function. In either case, leakage of fluid from the new vessels is decreased, and the concomitant scarring and loss of vision is likewise diminished or eliminated.
  • Another type of AMD occurs less commonly and is due to dead RPE cells; this is termed atrophic AMD. In either type of AMD, without treatment, many of the affected individuals will become legally blind.
  • Patients with early stage AMD can be diagnosed in an examination by the presence of drusen, an accumulation of dead outer segments of photoreceptor cells, under the RPE.
  • Hyaline excrescences that are located in Bruch's membrane (lamina basalis choroidea) also form.
  • the presence of large, soft drusen in the eye indicates a pre-stage of exudative AMD, and places patients at higher-than-average risk for ⁇ ieVfeF(3'ping
  • an anti-VEGF agent may have efficacy at an early stage of AMD (drusen), reducing or preventing its progression to full-fledged disease.
  • Laser coagulation therapy results in drusen disappearance or reduction, but causes formation of scar tissue.
  • sunitinib maleate in the inventive method may preclude the need for such therapy and thus alleviate this problem.
  • laser coagulation may address this problem by ameliorating both AMD and resulting scar tissue.
  • treatment involves targeting light (phototherapy) to the macular area to inhibit or impair the nascent defective blood vessels.
  • PDT uses a photosensitizing agent to locally and selectively destroy cells and/or tissues.
  • the agent is administered into the vessels of a patient and transported to the retina.
  • the appropriate wavelength of light is directed to this specific area to activate the agent.
  • Targeting low energy light to the area selectively activates the agent.
  • the activated agent generates free radicals (e.g., singlet oxygen, hydroxyl radicals, other activated chemical species) that destabilize and destroy the new vessels in this area. For example, it damages the walls of the choriocapillaries and neovascular tissue, and leads to an initial vascular thrombus that may occlude the vessels. . . .
  • PDT is generally directed to the lesion, but may also be administered to a generally circular area surrounding the lesion, up to about five disk diameters from the lesion. In one embodiment, PDT is administered to the lesion and an area about three to about five disk diameters from the lesion. In another embodiment, PDT is administered to the lesion and an area about one-half to about one disk diameter from the lesion. In still another embodiment, PDT is administered to the lesion.
  • the size of the applied laser treatments may be in the range of about 1 mm to about 9 mm.
  • tin ethyl etiopurpurin SnET2
  • SnET2 has lower persistence and severity of skin photosensitivity, it absorbs at longer wavelengths yielding better #tls ⁇ UetpehefraMhrft !; h ' as a higher extinction coefficient resulting in increased potency and efficiency, ease of synthesis, and ability to be produced in a highly pure form.
  • Protoporphyrin may be used as a photosensitizing agent.
  • Protoporphyrin IX is a photoactive compound that is endogenously formed from 5-aminolevulinic acid (ALA) in the biosynthetic pathway of heme.
  • ALA may be applied topically and is metabolized to protoporphyrin, the active photosensitizing agent.
  • Laser irradiation is usually at a wavelength in the range of about 630 nm, or alternatively in the range of 670 nm.
  • ALA may be administered orally in a bolus as an aqueous solution at a concentration of about 60 mg/kg body weight, or intravenously at a concentration of 30 mg/kg body weight.
  • photosensitizing agents include, but are not limited to, benzoporphyrin derivative monoacid tube A (BPD-MA) and mono-l-aspartyl chlorine 6 (NPe6), with absorbance maxima in the range of about 660-690 nm, ATX- 106, and indocyanine green (ICG).
  • BPD-MA benzoporphyrin derivative monoacid tube A
  • NPe6 mono-l-aspartyl chlorine 6
  • ICG indocyanine green
  • Verteporfin a synthetic, chlorin-like porphyrin
  • Verteporfin may be intravenously injected at a dose of about 1-2 mg/kg, and activated by light at 50 J/cm2 (absorbance peak of drug) from a non-thermal laser (for example, a diode laser) set at an intensity of 600 mW/cm 2 and a wavelength of 689 nm.
  • a non-thermal laser for example, a diode laser set at an intensity of 600 mW/cm 2 and a wavelength of 689 nm.
  • PDT has been reported to be of some benefit to patients having AMD.
  • one study (Arch. Ophthalmol. 17:1329-1345, 1999) evaluated PDT in four " hundred and two eyes from patients diagnosed with AMD in at least one eye. Treatment outcome was assessed by comparing the patient's ability to accurately read a conventional vision chart (one having about five letters per line) pre-treatment and post-treatment.
  • a conventional vision chart one having about five letters per line
  • 61 % of the eyes (246/402) lost fewer than 15 letters (that is, the patient lost less than about three lines on a standard visual chart), while 46% of the eyes (96/207) from patients undergoing treatment with a placebo lost fewer than 15 letters (p ⁇ 0.001 ).
  • Ranibizumab has been administered by intravitreal injection in combination with verteporfin PDT to determine its effect on choroidal neovascularization. The combination caused a greater reduction in angiographic leakage than PDT only, as reported by Husain et a!., Apr. 2005 Arch Opthamol. 123:309, which is expressly incorporated by reference herein in its entirety.
  • ranibizumab is a derivative of the full-length antibody bevacizumab (Fab fragment), and is further modified to increase its affinity for VEGF.
  • the method prevents, alleviates, or delays the onset of AMD in a patient by administering PDT simultaneously or concomitantly with sunitinib maleate.
  • the method also prevents or delays the progression of AMD, and reduces further loss of vision in a patient having AMD, by administering PDT simultaneously or concomitantly with sunitinib maleate.
  • the combination of PDT with sunitinib maleate enhances alleviation of AMD and/or its symptoms or sequelae.
  • enhanced alleviation encompasses any reduction in the duration, severity, type, etc. of the underlying pathology and/or its symptoms, and is not limited to complete efficacy, although therapeutic efficacy is included.
  • the method thus encompasses preventing or delaying the onset of AMD, and/or maintaining visual acuity and preventing further loss of vision in patients with AMD.
  • the method may generate free radicals and other activated chemical species that destabilize and destroy the new vessels via PDT, and reduce the formation of new blood vessels via anti-VEGF action of sunitinib maleate.
  • inventive method and device In addition to AMD, other ocular conditions may be treated with the inventive method and device. These conditions include, but are not limited to, blepharitis, conjunctivitis, keratitis, episcleritis, scleritis, papillitis (optic neuritis), uveitis, and/or endophthalmitis.
  • inventive method and device also may be used to reduce postsurgical inflammation. ⁇ uv-w#j- ' iHs--.fep3oH:eiGi-that another anti-VEGF agent, bevacizumab, at a dose of 1 mg was administered as a single intravitreal injection to a patient with neovascular age- related macular degeneration.
  • sunitinib maleate is administered without PDT or any other type of phototherapy.
  • sunitinib maleate alone, or in combination with another agent provides therapy without phototreatment.
  • the inventive method may be used in conjunction with other therapies such as thermal laser coagulation, it may also be used without PDT, laser treatment, etc. but may include the addition of anti-proliferative agents, steroids, etc. administered with the inventive device or separately (e.g., subconjunctival depot steroid therapy), as known to one skilled in the art.
  • both PDT and sunitinib maleate are administered, but their administration is not restricted to a particular sequence.
  • PDT is administered and, essentially simultaneously with or immediately thereafter, sunitinib maleate is administered.
  • PDT is administered and sunitinib maleate is administered in the same treatment session, within a time frame of a few minutes or within a few hours.
  • PDT is administered and sunitinib maleate is administered after an interval from about one day up to about 90 days.
  • sunitinib maleate is administered and, essentially simultaneously with or immediately thereafter, PDT is administered.
  • sunitinib maleate is administered and PDT is administered in the same treatment session, within a time frame of a few minutes or within a few hours.
  • sunitinib maleate is administered and PDT is administered after an interval from about one day up to about 90 days.
  • PDT and sunitinib maleate are not administered essentially simultaneously, either may be administered first.
  • the patient after administering the photosensitive agent (verteporfin, protoporphyrin, SnET2, NPe6, ATX-106, ICG, etc.), the patient is treated using a laser to administer low energy levels of light at a wavelength appropriate to activate the photosensitive agent.
  • Treatment with sunitinib maleate is then initiated • -essentially' 1 - - 1 SMyWeOUsIy or concomitantly.
  • Essentially simultaneous treatment includes administration of both sunitinib maleate and low energy light within the same treatment session.
  • Concomitant treatment includes administration either immediately thereafter or within a few hours, within 24 hours, or after an interval from about one day to ninety days.
  • the patient is treated with sunitinib maleate, and is thereafter treated with PDT.
  • the photosensitive agent may be administered either before or after sunitinib maleate treatment, depending upon a variety of factors such as the specific photosensitive agent used, the specific treatment protocol, etc. PDT is then essentially simultaneously or concomitantly initiated, as previously described. Factors such as patient comfort, tolerance to treatment, and convenience may be considered in selecting the appropriate treatment regime.
  • the combination of PDT and sunitinib maleate may provide synergistic benefits.
  • One benefit is that the combined therapies induce regression of neovascular tissue. Besides patients with AMD, patients with diabetes who are particularly prone to proliferative retinopathy, a frequent cause of blindness could benefit from this treatment.
  • Another benefit is that the combined therapies do not produce additional neovascular tissue because of anti-angiogenic function. The combination of the two treatments thereby reduces the need for repetitive PDT treatments that damage the retina and further reduce the patient's visual acuity.
  • the extent of burn stimulus response was scored as follows: 0 (no blister, not raised above corneal surface), +1 (small blister, raised slightly above the surface), +2 (medium blister, raised moderately above the surface), +3 (large blister). Only corneas with a burn stimulus score of +2 or higher were included for the calculation of the mean burn stimulus and neovascularization scores in each group. All photographs were converted to high-resolution digital forms by scanner (Cano scan 9900F, Canon, Tokyo Japan). The corneal surface covered with neovascular vessels was measured on the photographs as the percentage of the total area of the cornea. Image analysis was performed on each cornea using an image processing and analysis software program (Image J 1.31v.
  • the area of neovascularization was measured in terms of pixels and its ratio to the entire corneal area was determined as the percentage of corneal neovascularization.
  • a drawing of corneal blood vessels was made by one investigator to compare with digital photos and to ensure that no vascular area was missed during calculation of percent area. After scoring the burn stimulus and the percentage of neovascularization for both groups, the animals were sacrificed on the seventh day.
  • the burn stimulus score was +2 or higher in all eyes.
  • the mean burn stimulus scores were not statistically different between the treatment and the placebo groups (P>0.05, Mann-Whitney U test).
  • FIG. 4 is a photograph of a representative bevacizumab-treated eye
  • FIG. 5 is a photograph of a representative control eye. The difference was statistically significant (p ⁇ 0.02, Mann Whitney test).
  • bevacizumab-treated eyes had - less corneal neovascularization than control eyes.
  • corneal neovascularization covered, on average, 38.2 ⁇ 15.5% (mean ⁇ standard deviation (SD) of the corneal surface.
  • SD mean ⁇ standard deviation
  • corneal neovascularization covered, on average, 63.5 ⁇ 5.0% (mean ⁇ SD) of the corneal surface (p ⁇ 0.02, Mann-Whitney test).
  • Topically administered bevacizumab at 4 mg/ml decreased corneal neovascularization by 40%.
  • Example 1 Animals are treated and prepared as in Example 1 , except that bevacizumab is administered by intravitreal injection using a 30 g needle. Corneal neovascularization in treated eyes is reduced over untreated eyes.
  • Example 1 Animals are treated and prepared as in Example 1 , except that bevacizumab is administered by subconjunctival injection using a 30 g needle. Corneal neovascularization in treated eyes is reduced over untreated eyes.
  • Example 1 Animals are treated and prepared as in Example 1 , except that bevacizumab is administered by subretinal injection using a 30 g needle. Corneal neovascularization in treated eyes is reduced over untreated eyes.
  • Example 1 Animals are treated and prepared as in Example 1 , except that bevacizumab is administered by retrobulbar injection using a 30 g needle. Corneal neovascularization in treated eyes is reduced over untreated eyes.
  • Animals are treated and prepared as in any of Example 1-20, except that the agent is administered using an intraocular device. Corneal neovascularization in treated eyes is reduced over untreated eyes.
  • VEGF R1 vascular endothelial cells
  • CECs choroidal endothelial cells
  • the stimulants selected to induce inflammation were PMA and/or VEGF.
  • the corticosteroids deoxycorticosterone acetate (DOCA), fludrocortisone acetate (FCA) and triamcinolone acetonide (TA) were used to treat stimulated cells at dosages shown previously to reduce VEGF R1 expression in response to PMA stimulation.
  • the corticosteroids were used with or without 0.8 mg/ml Avastin (Spitzer efal., 2006).
  • Avastin plus DOCA (24.2% reduction) and Avastin plus FCA (25.5% reduction) produced a noticeable reduction in the individual treatments.
  • the magnitude of the reduction in VEGF R1 in He ⁇ ji ⁇ iSef ' td ⁇ -pltiS ⁇ vastin 39.9% reduction was greater than the effects of either agent alone (FIG. 8).
  • bevacizumab (Avastin) significantly enhanced the effects of the corticosteroids tested.
  • Such combinations may affect both the steroid dependent and independent pathways involved in inflammation and oedema.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à un procédé d'administration d'un agent anti-facteur croissance endothéliale vasculaire pour l'amélioration de l'inflammation à un site dans l'organisme qui peut être l'oeil, une articulation, le cerveau ou autres ou pour la réduction de la néovascularisation cornéenne. Dans un mode de réalisation, un ou plusieurs autres agents, tels que des agents anti-inflammatoires non stéroïdes, stéroïdes et autres peuvent être inclus avec l'agent anti-facteur croissance endothéliale vasculaire. L'agent anti-facteur croissance endothéliale vasculaire peut être le bevacizumab, le ranibizumab, le sunitinib maléate, le pegaptanib, et autres.
PCT/US2006/037332 2005-09-26 2006-09-26 Administration d'un agent pour l'amelioration de l'inflammation WO2007038453A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/234,970 US20070071754A1 (en) 2005-09-26 2005-09-26 Method to ameliorate inflammation
US11/234,970 2005-09-26
US11/348,465 US20070072933A1 (en) 2005-09-26 2006-02-06 Delivery of an ocular agent
US11/348,017 2006-02-06
US11/348,465 2006-02-06
US11/348,017 US20070071756A1 (en) 2005-09-26 2006-02-06 Delivery of an agent to ameliorate inflammation

Publications (2)

Publication Number Publication Date
WO2007038453A2 true WO2007038453A2 (fr) 2007-04-05
WO2007038453A3 WO2007038453A3 (fr) 2007-11-29

Family

ID=37806769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037332 WO2007038453A2 (fr) 2005-09-26 2006-09-26 Administration d'un agent pour l'amelioration de l'inflammation

Country Status (1)

Country Link
WO (1) WO2007038453A2 (fr)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007038730A1 (de) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Nachweis des menschlichen Vascular Endothelial Growth Factor
WO2009021150A3 (fr) * 2007-08-08 2009-03-26 California Pacific Med Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
WO2009105534A3 (fr) * 2008-02-21 2009-11-05 Ista Pharmaceuticals Ains ophtalmiques utilisés comme adjuvants
WO2010069073A1 (fr) * 2008-12-16 2010-06-24 Qlt Inc. Combinaison d'une thérapie photodynamique et d'agents anti-vegf dans le traitement d'une néovascularisation choroïdienne indésirable
WO2010119306A1 (fr) * 2009-04-15 2010-10-21 Fondazione Irccs Istituto Nazionale Dei Tumori Utilisation d'inhibiteurs de multiples kinases dans le traitement d'une hyperperméabilité vasculaire
WO2013188283A1 (fr) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Composition pharmaceutique ophtalmique topique contenant du sunitinib
US8747852B1 (en) 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
US20150045296A1 (en) * 2012-03-29 2015-02-12 Xavier University Of Louisiana Method for treating diabetic retinopathy
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
EP2242464B2 (fr) † 2007-12-20 2017-03-01 University Of Southern California Appareil pour distribuer des agents thérapeutiques
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9980901B2 (en) 2015-06-06 2018-05-29 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10154994B2 (en) 2015-06-22 2018-12-18 Allgenesis Biotherapeutics, Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
RU2676303C2 (ru) * 2013-07-11 2018-12-27 Новартис Аг Использование антагониста vegf для лечения ретролентальной фиброплазии
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10688092B2 (en) 2016-06-02 2020-06-23 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US12156873B2 (en) 2018-05-25 2024-12-03 Ads Therapeutics Llc Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2894940T3 (es) 2010-08-05 2022-02-16 Forsight Vision4 Inc Aparato para tratar un ojo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1180024A (ja) * 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050058688A1 (en) * 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
US20050192264A1 (en) * 2004-02-04 2005-09-01 Penfold Philip L. Slow release steroid composition
WO2005084188A2 (fr) * 2004-02-25 2005-09-15 Massachusetts Eye & Ear Infirmary Marqueurs d'inflammation systemique et degenerescence maculaire liee a l'age (amd)
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
AU2006214658A1 (en) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
WO2007011873A2 (fr) * 2005-07-15 2007-01-25 Genentech, Inc. Procede permettant de traiter des maladies neovasculaires intraoculaires
WO2007047626A1 (fr) * 2005-10-14 2007-04-26 Alcon, Inc. Traitement de combinaison comprenant de l'acetate d'anecortave et du bevacizumab ou du ranibizumab pour une angiogenese oculaire pathologique

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435510B2 (en) 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
WO2009021150A3 (fr) * 2007-08-08 2009-03-26 California Pacific Med Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
US9340788B2 (en) 2007-08-08 2016-05-17 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
DE102007038730A1 (de) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Nachweis des menschlichen Vascular Endothelial Growth Factor
EP2242464B2 (fr) † 2007-12-20 2017-03-01 University Of Southern California Appareil pour distribuer des agents thérapeutiques
WO2009105534A3 (fr) * 2008-02-21 2009-11-05 Ista Pharmaceuticals Ains ophtalmiques utilisés comme adjuvants
JP2011513229A (ja) * 2008-02-21 2011-04-28 イスタ・ファーマスーティカルズ・インコーポレイテッド 補助剤としての眼科用ｎｓａｉｄ
US9226917B2 (en) 2008-12-16 2016-01-05 Valeant Pharmaceuticals International, Inc. Photodynamic therapy for conditions of the eye
AU2009327266B2 (en) * 2008-12-16 2015-10-29 Valeant Pharmaceuticals International, Inc. Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature
WO2010069073A1 (fr) * 2008-12-16 2010-06-24 Qlt Inc. Combinaison d'une thérapie photodynamique et d'agents anti-vegf dans le traitement d'une néovascularisation choroïdienne indésirable
JP2012512184A (ja) * 2008-12-16 2012-05-31 キュー エル ティー インク． 眼の状態に関する光線力学的療法
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
US10813788B2 (en) 2009-01-29 2020-10-27 Forsight Vision4, Inc. Implantable therapeutic device
US10656152B2 (en) 2009-01-29 2020-05-19 Forsight Vision4, Inc. Posterior segment drug delivery
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US11642310B2 (en) 2009-01-29 2023-05-09 Forsight Vision4, Inc. Posterior segment drug delivery
WO2010119306A1 (fr) * 2009-04-15 2010-10-21 Fondazione Irccs Istituto Nazionale Dei Tumori Utilisation d'inhibiteurs de multiples kinases dans le traitement d'une hyperperméabilité vasculaire
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US10265215B2 (en) 2010-08-05 2019-04-23 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US11786396B2 (en) 2010-08-05 2023-10-17 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US11679027B2 (en) 2010-08-05 2023-06-20 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US11065151B2 (en) 2010-11-19 2021-07-20 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US11813196B2 (en) 2011-06-28 2023-11-14 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10653554B2 (en) 2011-09-16 2020-05-19 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10603209B2 (en) 2012-02-03 2020-03-31 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US9636299B2 (en) * 2012-03-29 2017-05-02 Xavier University Of Louisiana Method for treating diabetic retinopathy
US20150045296A1 (en) * 2012-03-29 2015-02-12 Xavier University Of Louisiana Method for treating diabetic retinopathy
WO2013188283A1 (fr) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Composition pharmaceutique ophtalmique topique contenant du sunitinib
US9161978B2 (en) 2012-12-28 2015-10-20 Randal Tanh Hoang Pham Methods of treatment of pterygium using an anti-VEGF agent
WO2014105978A1 (fr) * 2012-12-28 2014-07-03 Pham Randal Tanh Hoang Procédés de traitement utilisant le bévacizumab
US8747852B1 (en) 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
US10556008B2 (en) 2012-12-28 2020-02-11 Randal Tanh Hoang Pham Methods of treatment of keloid using an anti-VEGF agent
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US11510810B2 (en) 2013-03-28 2022-11-29 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US12115102B2 (en) 2013-03-28 2024-10-15 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
RU2676303C2 (ru) * 2013-07-11 2018-12-27 Новартис Аг Использование антагониста vegf для лечения ретролентальной фиброплазии
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US11337853B2 (en) 2014-07-15 2022-05-24 Forsight Vision4, Inc. Ocular implant delivery device and method
US12343283B2 (en) 2014-07-15 2025-07-01 Forsight Vision4, Inc. Ocular implant delivery device and method
US10765677B2 (en) 2014-08-08 2020-09-08 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10363255B2 (en) 2014-08-08 2019-07-30 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US12251336B2 (en) 2014-11-10 2025-03-18 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US11110001B2 (en) 2014-11-10 2021-09-07 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10149820B2 (en) 2015-06-06 2018-12-11 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US12186424B2 (en) 2015-06-06 2025-01-07 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium recurrence
US10980741B2 (en) 2015-06-06 2021-04-20 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium recurrence
US10149819B2 (en) 2015-06-06 2018-12-11 Cloudbreak Therapeutics, Llc Compositions and methods for treating hyperemia
CN108135737A (zh) * 2015-06-06 2018-06-08 克劳德布雷克医疗有限责任公司 用于治疗翼状胬肉的组合物和方法
US9987223B2 (en) 2015-06-06 2018-06-05 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US9980901B2 (en) 2015-06-06 2018-05-29 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US10154994B2 (en) 2015-06-22 2018-12-18 Allgenesis Biotherapeutics, Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
US11369600B2 (en) 2015-06-22 2022-06-28 Allgenesis Biotherapeutics Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US12201556B2 (en) 2015-11-20 2025-01-21 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US12102560B2 (en) 2016-04-05 2024-10-01 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US11246864B2 (en) 2016-06-02 2022-02-15 Ads Therapeutics Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US11911379B2 (en) 2016-06-02 2024-02-27 Ads Therapeutics Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US10688092B2 (en) 2016-06-02 2020-06-23 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
US12156873B2 (en) 2018-05-25 2024-12-03 Ads Therapeutics Llc Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Also Published As

Publication number Publication date
WO2007038453A3 (fr) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2007038453A2 (fr) Administration d'un agent pour l'amelioration de l'inflammation
US20070072933A1 (en) Delivery of an ocular agent
US20080003219A1 (en) Delivery of an ocular agent
US20070071756A1 (en) Delivery of an agent to ameliorate inflammation
US20080167600A1 (en) Device for delivery of an agent to the eye and other sites
ES2326550T3 (es) Uso de un macrolido para restablecer la sensacion corneal.
EP1904056B1 (fr) Utilisation d'un macrolide pour restaurer la sensation cornéenne
Sivaprasad et al. Intravitreal steroids in the management of macular oedema
US20110104155A1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops
WO2010125416A1 (fr) Administration de médicaments dans le segment antérieur et le segment postérieur de l'oeil
JP2009511604A (ja) 緑内障の原発性形態および続発性形態を処置するための方法
JP2007523911A (ja) 眼病変治療用テトラサイクリン誘導体
JP2011530496A (ja) 眼新生血管形成症状の治療のためのソラフェニブを含む眼科用医薬組成物
US20040127472A1 (en) Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
KR20010113918A (ko) 후안부 안과 질환을 치료하고 예방하기 위한 방법 및 조성물
US20050261243A1 (en) Antiprostaglandins for the treatment of ocular pathologies
Peyman et al. Combination therapies in ophthalmology: implications for intravitreal delivery
Cholkar et al. Compositions, formulation, pharmacology, pharmacokinetics, and toxicity of topical, periocular, and intravitreal ophthalmic drugs
US20070043006A1 (en) Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
Pérez-Sarriegui et al. Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant
Paccola et al. Anti‐inflammatory efficacy of a single posterior subtenon injection of triamcinolone acetonide versus prednisolone acetate 1% eyedrops after pars plana vitrectomy
Agrawal et al. Applications, model study and commercial utilization (patents) of ophthalmic route as drug delivery site
de Zea et al. Dexamethasone intravitreal implant for treatment of persistent macular oedema in Birdshot retinochoroidopathy
WO2025090106A1 (fr) Compositions et méthodes de traitement de la dégénérescence neuronale dans le glaucome et états associés
EP4558147A1 (fr) Méthodes et compositions pour le traitement du glaucome et des affections associées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06815379

Country of ref document: EP

Kind code of ref document: A2